Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21326682 | 0.86 | CYP1A2 (0.48) | IRAK4CYP1A2CYP2C9MAPTALDH1A1 | |
| SCHEMBL21326643 | 0.81 | IRAK4 (0.52) | IRAK4MAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL23093807 | 0.80 | CYP1A2 (0.43) | IRAK4CYP1A2CYP2C9MAPTALDH1A1 | |
| SCHEMBL21326707 | 0.80 | CYP1A2 (0.41) | IRAK4CYP1A2CYP2C9MAPTALDH1A1 | |
| SCHEMBL19030693 | 0.79 | IRAK4 (0.48) | IRAK4CYP1A2CYP2C9MAPTALDH1A1 | |
| SCHEMBL21326665 | 0.78 | CYP2C9 (0.41) | IRAK4CYP1A2CYP2C9MAPTALDH1A1 | |
| SCHEMBL21326647 | 0.74 | IRAK4 (0.38) | IRAK4MAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL21326713 | 0.73 | DPP4 (0.39) | CYP1A2CYP2C9MAPTALDH1A1CYP2C19 | |
| SCHEMBL21326679 | 0.73 | MAPT (0.50) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL21326701 | 0.73 | IRAK4 (0.44) | IRAK4CYP1A2CYP2C9MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434250-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| CN-109890829-B | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20200262845-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200262845-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3535273-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262845-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885CYP1A2 3169/4885CYP2C9 3282/4885 |
| US-11434250-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885CYP1A2 3169/4885CYP2C9 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.